Quantcast
Last updated on April 20, 2014 at 19:30 EDT

Latest Novartis AG Stories

2013-09-18 08:25:31

NEW YORK, September 18, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting Pfizer Inc. (NYSE: PFE), Merck & Co. Inc. (NYSE: MRK), Rockwell Medical Technologies Inc. (NASDAQ: RMTI), GlaxoSmithKline plc (NYSE: GSK), and Novartis AG (NYSE: NVS). Today's readers may access these reports free of charge - including full price targets, industry analysis and...

2013-08-21 16:25:57

- Novartis plans to ship a minimum of 30 million doses of its seasonal influenza vaccines to US customers for the 2013-2014 season CAMBRIDGE, Mass., Aug. 21, 2013 /PRNewswire/ -- Novartis announced today that it has begun shipment of its seasonal influenza vaccines to customers in the US market for the 2013-2014 season. Novartis plans to ship a minimum of 30 million doses of its influenza vaccines to the US market, including Fluvirin (Influenza Virus Vaccine), approved for use in people 4...

2013-08-14 08:27:26

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, August 14, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Johnson & Johnson (NYSE: JNJ), Sanofi SA (NYSE: SNY), AstraZeneca PLC (NYSE: AZN), Novartis AG (NYSE: NVS), and GlaxoSmithKline plc (NYSE: GSK). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links...

2013-08-01 20:21:18

- Meningococcal disease is a leading cause of bacterial meningitis, a rapidly progressing disease that can lead to death in otherwise healthy children[2,3] CAMBRIDGE, Mass., Aug. 1, 2013 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) approved Menveo(®) (Meningococcal [Groups A, C, Y and W-135] Oligosaccharide Diphtheria CRM197 Conjugate Vaccine) to help prevent meningococcal disease caused by four strains of the bacterium Neisseria...

2013-07-17 08:26:53

Editor Note: For more information about this release, please scroll to bottom LONDON, July 17, 2013 /PRNewswire/ -- On Tuesday, July 16, 2013, shares in healthcare companies ended mostly lower, tracking losses in the broader market which slipped following a mixed batch of economic and earnings reports. Investors also exercised caution ahead of Fed Reserve Chairman Ben Bernanke's semi-annual testimony to Congress on Wednesday. The major movers in the sector included Dendreon...

2013-06-03 12:28:53

- Investigational compound LDK378 is a selective inhibitor of ALK1, a target found in metastatic non-small cell lung cancer (NSCLC) EAST HANOVER, N.J., June 3, 2013 /PRNewswire/ -- Novartis today announced data on its investigational compound LDK378 showing a marked clinical response in 78 patients with anaplastic lymphoma kinase positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who had progressed during or after crizotinib therapy or had not been previously treated...

2013-06-02 08:20:17

-- A 22% reduction in the risk of disease progression was seen with the addition of everolimus, an mTOR inhibitor, to trastuzumab and vinorelbine in heavily pretreated patients(1) EAST HANOVER, N.J., June 2, 2013 /PRNewswire/ -- Novartis today presented results from a pivotal Phase III trial of a treatment regimen including Afinitor(®) (everolimus) tablets in women with human epidermal growth factor receptor-2 positive (HER2 positive) advanced breast cancer who received prior...

2013-05-29 00:23:45

- Latest Phase III research on Afinitor® in advanced HER2 positive breast cancer EAST HANOVER, N.J., May 29, 2013 /PRNewswire/ -- Novartis will present new findings in the treatment of advanced cancers and other diseases with 170 abstracts at two prominent medical meetings. Research across the extensive Novartis product portfolio and pipeline showcases the progress in advancing care for patients with cancer and hematological diseases. Clinical data from multiple...

2013-04-25 12:27:39

-- Power of One donation campaign harnesses the latest web and mobile technology to rally the global public to fight malaria BASEL, Switzerland, April 25, 2013 /PRNewswire/ -- Novartis and Malaria No More, a leading global charity determined to end malaria deaths, announced today that they are joining forces on the Power of One campaign to help close the treatment gap and accelerate progress in the fight against malaria. Over the next three years, Novartis will support the...

2013-03-08 08:23:37

PARSIPPANY, N.J., March 8, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today confirmed that it has filed with the U.S. Food and Drug Administration (FDA) an amendment to its Abbreviated New Drug Application (ANDA) for Rivastigmine Transdermal System to include the 13.3 mg per 24 hours dosage strength. Actavis' ANDA product is a generic version of Novartis' Exelon(®) Patch, which is a prescription medicine used to treat people with mild to moderate dementia associated with Alzheimer's...